Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
Adult
Aged
Amides
/ therapeutic use
Antiviral Agents
/ therapeutic use
COVID-19
/ blood
Cytokines
/ blood
Drug Combinations
Female
Humans
Lopinavir
/ therapeutic use
Male
Middle Aged
Pyrazines
/ therapeutic use
Retrospective Studies
Ritonavir
/ therapeutic use
SARS-CoV-2
/ isolation & purification
COVID-19 Drug Treatment
COVID-19
Cytokines storm
Flow cytometry
SARS-CoV-2
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
12
2020
revised:
07
01
2021
accepted:
14
01
2021
pubmed:
26
2
2021
medline:
10
4
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has infected 86,4 M patients and resulted in 1,86 M deaths worldwide. Severe COVID-19 patients have elevated blood levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor (TNF)α, IL-8 and interferon (IFN)γ. To investigate the effect of antiviral treatment serum cytokines in severe COVID-19 patients. Blood was obtained from 29 patients (aged 32-79 yr) with laboratory-confirmed COVID-19 upon admission and 7 days after antiviral (Favipiravir or Lopinavir/Ritonavir) treatment. Patients also received standard supportive treatment in this retrospective observational study. Chest computed tomography (CT) scans were evaluated to investigate lung manifestations of COVID-19. Serum was also obtained and cytokines levels were evaluated. 19 age- and gender-matched healthy controls were studied. Anti-viral therapy significantly reduced CT scan scores and the elevated serum levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). In contrast, serum levels of IL-6, IL-8 and IFNγ were elevated at baseline in COVID-19 subjects compared to healthy subjects with IL-6 (p = 0.006) and IL-8 (p = 0.011) levels being further elevated after antiviral therapy. IL-1β (p = 0.01) and TNFα (p = 0.069) levels were also enhanced after treatment but baseline levels were similar to those of healthy controls. These changes occurred irrespective of whether patients were admitted to the intensive care unit. Antiviral treatments did not suppress the inflammatory phase of COVID-19 after 7 days treatment although CT, CRP and LDH suggest a decline in lung inflammation. There was limited evidence for a viral-mediated cytokine storm in these COVID-19 subjects.
Sections du résumé
BACKGROUND
BACKGROUND
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has infected 86,4 M patients and resulted in 1,86 M deaths worldwide. Severe COVID-19 patients have elevated blood levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor (TNF)α, IL-8 and interferon (IFN)γ.
OBJECTIVE
OBJECTIVE
To investigate the effect of antiviral treatment serum cytokines in severe COVID-19 patients.
METHODS
METHODS
Blood was obtained from 29 patients (aged 32-79 yr) with laboratory-confirmed COVID-19 upon admission and 7 days after antiviral (Favipiravir or Lopinavir/Ritonavir) treatment. Patients also received standard supportive treatment in this retrospective observational study. Chest computed tomography (CT) scans were evaluated to investigate lung manifestations of COVID-19. Serum was also obtained and cytokines levels were evaluated. 19 age- and gender-matched healthy controls were studied.
RESULTS
RESULTS
Anti-viral therapy significantly reduced CT scan scores and the elevated serum levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). In contrast, serum levels of IL-6, IL-8 and IFNγ were elevated at baseline in COVID-19 subjects compared to healthy subjects with IL-6 (p = 0.006) and IL-8 (p = 0.011) levels being further elevated after antiviral therapy. IL-1β (p = 0.01) and TNFα (p = 0.069) levels were also enhanced after treatment but baseline levels were similar to those of healthy controls. These changes occurred irrespective of whether patients were admitted to the intensive care unit.
CONCLUSION
CONCLUSIONS
Antiviral treatments did not suppress the inflammatory phase of COVID-19 after 7 days treatment although CT, CRP and LDH suggest a decline in lung inflammation. There was limited evidence for a viral-mediated cytokine storm in these COVID-19 subjects.
Identifiants
pubmed: 33631512
pii: S1567-5769(21)00043-6
doi: 10.1016/j.intimp.2021.107407
pmc: PMC7826095
pii:
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Cytokines
0
Drug Combinations
0
Pyrazines
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
favipiravir
EW5GL2X7E0
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
107407Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
J Immunol. 1993 Mar 15;150(6):2316-21
pubmed: 8450214
Front Immunol. 2020 Aug 26;11:2037
pubmed: 32983152
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Clin Invest. 1989 Oct;84(4):1045-9
pubmed: 2677047
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
J Clin Immunol. 2020 Oct;40(7):974-976
pubmed: 32648027
Front Immunol. 2020 May 15;11:1061
pubmed: 32574262
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
JAMA. 2020 Oct 6;324(13):1279-1281
pubmed: 32915201
Crit Care. 2020 Oct 29;24(1):627
pubmed: 33121512
Tanaffos. 2020 Nov;19(2):91-99
pubmed: 33262795
Nat Rev Drug Discov. 2020 Sep;19(9):577
pubmed: 32760013
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Radiology. 2005 Sep;236(3):1067-75
pubmed: 16055695
Nat Rev Immunol. 2005 Dec;5(12):917-27
pubmed: 16322745
Signal Transduct Target Ther. 2020 May 29;5(1):84
pubmed: 32467561
Eur J Radiol. 2020 Jun;127:109009
pubmed: 32325282
Ann Intern Med. 2020 Sep 15;173(6):499-501
pubmed: 32422085
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
Nat Rev Drug Discov. 2012 Aug;11(8):633-52
pubmed: 22850787